ReviewVaccines2025
Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of the effectiveness of polypeptide, virus-like particles, and viral vector vaccines for foot-and-mouth disease (2020-2025).Scientific reports · 2025Pooled it
- Pathogenicity and virulence of PRRSV: From regulated cell death reprogramming landscape and immune subversion to precision vaccinology.Virulence · 2026Review
- Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.Pharmaceutics · 2026Review
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Applications of Recombinant DNA Technology in Medicine: A Comprehensive Review.Molecular biotechnology · 2026Review
- From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.Virus research · 2026Review
- Review
- Bacterial Membrane Vesicles as Versatile Platforms for Systemic and Mucosal Vaccines.Vaccines · 2026Review
- Pharmaceutical design of mRNA vaccines for endemic infectious diseases: integrating antigen discovery with platform engineering.Clinical and experimental vaccine research · 2026Review
- HIV Membrane-Proximal External Region Scaffolded Immunogen as Killed Whole-Cell Genome-Reduced Vaccines.Viruses · 2026Article
- mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation.Frontiers in pharmacology · 2026Review
- Combating Drug-Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics.Pulmonary medicine · 2026Review
- Phosphorylation shapes antigen presentation and immune recognition: mechanistic insights and translational perspectives.Frontiers in immunology · 2026Review
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- Nanomaterials in Targeted Immunotherapy for Chronic Spontaneous Urticaria: Focusing on Immune Cell Modulation and Precision Treatment.International journal of nanomedicine · 2026Review
- From empirical vaccinology to predictive systems-based vaccine design: multi-omics integration, artificial intelligence, and global equity challenges.Frontiers in systems biology · 2026Review
- Immune interception in cancer: prioritizing vaccination in high-risk and premalignant settings.Frontiers in immunology · 2026Article
- Article
- Review
- Next-generation vaccines against bacterial pathogens: mRNA and beyond.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of complex and rapidly evolving pathogens necessitates innovative vaccine platforms that move beyond traditional methods. This review explores the transformative potential of next-generation vaccine technologies, focusing on the combined use of synthetic biology, nanotechnology, and systems immunology. Synthetic biology provides modular tools for designing antigenic components with improved immunogenicity, as seen in mRNA, DNA, and peptide-based platforms featuring codon optimization and self-amplifying constructs. At the same time, nanotechnology enables precise antigen delivery and controlled immune activation through engineered nanoparticles such as lipid-based carriers, virus-like particles, and polymeric systems to improve stability, targeting, and dose efficiency. Systems immunology aids these advancements by analyzing immune responses through multi-omics data and computational modeling, which assists in antigen selection, immune profiling, and adjuvant optimization. This approach enhances both humoral and cellular immunity, solving challenges like antigen presentation, response durability, and vaccine personalization. Case studies on SARS-CoV-2, Epstein-Barr virus, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.